Table 5.
Variable | Unadjusted | Adjusted | |||||
---|---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | Wald χ (2) | P value | |
Proximal CD4 count < 200 cells/mm3 | 1.42 | 0.80–2.52 | .23 | 1.69 | 0.88–3.26 | 2.46 | .12 |
CD4 nadir < 200 cells/mm3 | 1.33 | 0.77–2.31 | .31 | 1.43 | 0.78–2.63 | 1.31 | .25 |
VL (most recent) < 400 copies/mL | 0.78 | 0.45–1.37 | .39 | 0.64 | 0.33–1.27 | 1.63 | .20 |
Abacavir exposure | 0.87 | 0.47–1.64 | .67 | 0.79 | 0.38–1.65 | 0.40 | .52 |
Didanosine/stavudine exposure | 1.31 | 0.70–2.48 | .40 | 1.45 | 0.69–3.05 | 0.94 | .33 |
Zidovudine exposure | 0.64 | 0.36–1.15 | .14 | 0.66 | 0.34–1.28 | 1.50 | .22 |
PI exposure Continuous proximal CD4 count |
0.83 | 0.49–1.41 | .50 | 0.69 | 0.36–1.35 | 1.17 | .28 |
per 1-cell/mm3 decrease | 1.001 | 1.00–1.001 | .17 | 1.005 | 1.002–1.01 | 9.32 | .002 |
per 50-cell/mm3 decrease | 1.03 | 0.99–1.08 | 1.31 | 1.10–1.56 | |||
Continuous nadir CD4 | |||||||
per 1-cell/mm3 decrease | 1.001 | 1.00–1.001 | .35 | 1.006 | 1.00–1.01 | 9.28 | .002 |
per 50-cell/mm3 decrease | 1.03 | 0.96–1.11 | 1.37 | 1.12–1.67 |
CI, confidence interval; PI, protease inhibitor; VL, viral load.